Asia Pacific Narcolepsy Drugs Market

Asia Pacific Narcolepsy Drugs Market Size

The Asia Pacific narcolepsy drugs market was valued at USD 0.86 billion in 2024 and is projected to reach USD 2 billion by 2033, growing at a CAGR of 9.83% from 2024 to 2033.

MARKET DRIVERS

Growing Awareness and Early Diagnosis of Sleep Disorders

The active participation of healthcare facilities to raise awareness of the disorder and its symptoms is driving the growth of the narcolepsy drugs market in the Asia Pacific region. Other factors, such as growing concern about the benefits of early diagnosis of narcolepsy, coupled with government efforts to educate individuals and trained professionals about the disease, are accelerating market growth. Neurological disorders related to sleep are an emerging problem as the population ages at a rapid rate. The most common diagnoses other than narcolepsy were sleep apnea syndrome and sleep-wake schedule disorder in China. The prevalence rate of narcolepsy in southern China was recorded to be 0.035%. Extreme drowsiness affects most people, and sleep disturbances increase the risk associated with symptoms. In addition, cataplexy is expected to develop at a higher rate due to the sudden loss of muscle control by patients with cataplexy.

MARKET OPPORTUNITIES

Expanding Drug Portfolio and Focus on Narcolepsy Awareness

Narcolepsy without cataplexy will lead the narcolepsy drugs market in Asia Pacific during the prognostic period, owing to improving awareness of excessive daytime sleepiness with or with REM sleep patterns. Several organizations are focusing on spreading knowledge about the various sleep disorders, and their treatment options are leading to an increase in narcolepsy awareness programs. However, due to the low awareness and inaccurate depictions of the disease, most people with narcolepsy are undiagnosed. Without the diagnosis and care of a sleep specialist, the symptoms of narcolepsy can be misinterpreted as laziness or a character defect. They can limit educational and employment opportunities or lead to misdiagnosis. Additionally, the substantial portfolio of drugs for the treatment of narcolepsy is expected to positively impact the growth of the Asia Pacific narcolepsy market in the coming years. The spectrum of drugs involving sodium oxybate will increase the company portfolio.

MARKET CHALLENGES

Drug Side Effects, Abuse Risk, and Misdiagnosis Issues

The side effects and risks associated with ant narcoleptic drugs, primarily due to sodium oxybate causing central nervous system depressant, respiratory depression, seizures, and their potential for abuse. Another factor that will challenge the market can be late diagnosis and misdiagnosis of narcolepsy with other sleep disorders.

REPORT COVERAGE

COUNTRY LEVEL ANALYSIS

In 2024, the regional market in Australia dominated the studied market. It is forecasted to continue to be the largest share in the Asia Pacific market during the forecast period due to increased healthcare spending in this region, significant sedentary lifestyle changes, and growing awareness in the population about various sleep disorders. According to data from the journal Sleep Science in 2018, approximately 1 in 2,000 people are suffering from narcolepsy across the globe. Moreover, the Australian Institute of Health and Welfare stated that around two-thirds, i.e., 64% of the Australian population aged 18 years and more, are estimated to be overweight or obese and have higher chances of contracting the disorder.

It is estimated that the Asia Pacific regions like India, Singapore, Malaysia, and South Korea are anticipated to have lucrative growth due to higher prevalence in Japan and the presence of emerging economies, increased research and development initiatives to advance new drugs against narcolepsy. With recent improvements in knowledge about narcolepsy, drugs targeting hypocretin have been developed, with no permanent cure and only symptomatic relief.

The Chinese market is predicted to grow due to the increasing prevalence of unhealthy lifestyles, better reimbursement policies, and technological advancements for disease diagnosis. Moreover, the growing number of cases of narcolepsy leading to increased awareness of treatment and increased healthcare expenditure is driving the growth of the market.

KEY MARKET PLAYERS

Companies playing a leading role in the Asia Pacific Narcolepsy Drugs Market analyzed in this report are Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.

MARKET SEGMENTATION

This research report on the Asia Pacific narcolepsy drugs market has been segmented and sub-segmented into the following categories.

By Type

• Central Nervous System Stimulants
• Tricyclic Antidepressants
• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitor
• Others

By Indication

• Daytime Extreme Sleepiness
• Cataplexia
• Others

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of Asia Pacific